Chugai Applies For Additional Epogen Indication
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Chugai Pharmaceutical submitted an approval application Nov. 19 for an additional indication of chemotherapy-induced anemia for Epogen (epoetin alfa)